Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 21, 2026 16:05 ET | Source: PharmAla Biotech

PharmAla Issues Q2 Financial Statements and Grants Options

PharmAla files Q2 quarterly financials with increased customer deposits.
April 20, 2026 08:15 ET | Source: PharmAla Biotech

PharmAla Biotech Positioned to Supply U.S. Expanded Access Pathway for MDMA Established by Presidential Executive Order

PharmAla is positioned to supply the US market with MDMA, and is advancing its next-generation patented safer MDMA product for human dosing this year.
April 20, 2026 07:42 ET | Source: Psyence Biomedical Ltd.

Psyence BioMed Positioned as World's only Licensed Pharmaceutical Grade Ibogaine Supplier at Source

NEW YORK, April 20, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a clinical-stage biopharmaceutical company advancing nature-derived...
April 20, 2026 06:34 ET | Source: Silo Pharma, Inc.

Silo Pharma Positioned to Advance Treatment Targeting PTSD as President Trump Signs Executive Order Aimed at Accelerating Research and Treatment Based Upon Psychedelics

SPC-15 Intranasal PTSD Program Aligns with Federal Push to Fast-Track Novel Mental Health Therapies SARASOTA, Fla., April 20, 2026 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (NASDAQ: SILO), a...
April 18, 2026 21:28 ET | Source: ThinkCareBelieve

ThinkCareBelieve: Week 65 of President Trump’s Second Term Leading America to Greatness

Week 65 featured a high-energy mix of bold domestic innovation and assertive foreign policy, with a fiery TPUSA speech in Arizona telling of the progress.
April 17, 2026 09:15 ET | Source: Psyence Biomedical Ltd.

Psyence BioMed Welcomes U.S. Executive Action to Advance Research into Ibogaine

NEW YORK, April 17, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a clinical-stage biopharmaceutical company advancing nature-derived psilocybin...
April 08, 2026 09:15 ET | Source: Psyence Biomedical Ltd.

Psyence BioMed Expands Australian Clinical Site Network to Five Sites, Advancing NPX-5–Supported Clinical Activities

NEW YORK, April 08, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine...
March 23, 2026 09:00 ET | Source: PharmAla Biotech

Cortexa Advances Commercialisation of MDMA Supply in Australia

PharmAla provides an update on Cortexa, its Australian joint venture with Vitura Health.
March 12, 2026 12:18 ET | Source: Research and Markets

Psychedelic Drugs Market Trends and Global Forecasts Report 2026-2035: 45+ Developers Advance Ketamine and Psilocybin Therapies with Expanding Clinical Trials and Rising Regulatory Momentum

Dublin, March 12, 2026 (GLOBE NEWSWIRE) -- The "Psychedelic Drugs Market: Industry Trends and Global Forecasts - Distribution by Origin of Substance, Type of Psychedelic Substance, Target Disease...
March 11, 2026 09:15 ET | Source: Psyence Biomedical Ltd.

Corporate Update: Psyence BioMed Advances Vertically Integrated Pharmaceutical Platform Following PsyLabs Export Milestone

NEW YORK, March 11, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”) today reinforced how its strategic investment in PsyLabs strengthens its...